UK markets open in 5 hours 22 minutes
  • NIKKEI 225

    23,246.42
    -172.09 (-0.73%)
     
  • HANG SENG

    24,388.54
    -320.26 (-1.30%)
     
  • CRUDE OIL

    37.61
    +0.22 (+0.59%)
     
  • GOLD FUTURES

    1,878.20
    -1.00 (-0.05%)
     
  • DOW

    26,519.95
    -943.24 (-3.43%)
     
  • BTC-GBP

    10,185.74
    +10.11 (+0.10%)
     
  • CMC Crypto 200

    261.90
    -10.79 (-3.96%)
     
  • ^IXIC

    11,004.87
    -426.48 (-3.73%)
     
  • ^FTAS

    3,155.25
    -78.74 (-2.43%)
     

Vivoryon Therapeutics AG: Ordinary General Meeting of Shareholders of Vivoryon Therapeutics AG

·4-min read

DGAP-News: Vivoryon Therapeutics AG / Key word(s): AGM/EGM
01.10.2020 / 07:00
The issuer is solely responsible for the content of this announcement.

Ordinary General Meeting of Shareholders of Vivoryon Therapeutics AG


All proposed resolutions approved with large majority
 

HALLE (SAALE) / MUNICH, Germany, 01 October 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today that its shareholders approved all resolutions proposed by the Company's management and Supervisory Board at the Company's Annual General Meeting which took place on Wednesday, September 30, 2020, including:
 

 

47.72 % of the voting shares were represented at the 2020 Vivoryon Therapeutics AG AGM.
 

All resolutions proposed by the Company's management and Supervisory Board were approved at the meeting with a large majority. The voting results can be found on the Company's website:
www.vivoryon.com/investors-news/ordinary-general-meeting-of-shareholders-2020

Objection was declared for a total of less than 2% of the total outstanding voting rights and recorded in the minutes of the Annual General Meeting. Therefore, the Management Board is instructed to complete the transfer of the registered office to the Netherlands, the conversion and the related amendment of the Articles of Association.


Dr. Ulrich Dauer, Chief Executive Officer of Vivoryon Therapeutics AG, said: "We would like to take this opportunity to thank all of our employees, advisors and consultants, as well as the members of the Supervisory Board, partners and shareholders for their commitment, trust and support."

###

For more information, please contact:
Vivoryon Therapeutics AG
Dr. Ulrich Dauer, CEO
Email: contact@vivoryon.com

Trophic Communications
Gretchen Schweitzer / Joanne Tudorica
Tel: +49 172 861 8540 / +49 176 2103 7191
Email: vivoryon@trophic.eu

 

About Vivoryon Therapeutics AG
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon Therapeutics is advancing its lead product, varoglutamstat (PQ912), in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury.
www.vivoryon.com

 

Forward Looking Statements

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.


01.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Vivoryon Therapeutics AG

Weinbergweg 22

06120 Halle/Saale

Germany

Phone:

+49 (0)345 555 9900

Fax:

+49 (0)345 555 9901

E-mail:

contact@vivoryon.com

Internet:

www.vivoryon.com

ISIN:

DE0007921835

WKN:

792183

Listed:

Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam

EQS News ID:

1138095


 

End of News

DGAP News Service

show this
show this